Germany's Merck KGaA said on Thursday it is in late-stage talks to acquire U.S.-based SpringWorks Therapeutics for about $3.5 ...

SHANGHAI (Reuters) -The Beijing-based American Chamber of Commerce said on Friday that companies in the pharmaceutical sector ...

Futures trade pointed to a higher open on European stock markets, adding to a second straight weekly gain as the shock wears ...

Patients will likely eventually see higher prices and drug shortages under President Trump's plan to assess tariffs on ...

Merck’s first-quarter net income increased as sales of its Keytruda cancer drug rose, but the Big Pharma company cut its 2025 ...

Halozyme claims Merck infringed on patents in developing a subcutaneous form of Keytruda. Elsewhere, Vanda’s challenge to an ...

Merck KGaA has confirmed that it is in late-stage discussions with SpringWorks, valuing the deal at a price of around $47 per ...

Merck (MRK) stock rises as Summit Therapeutics (SMMT) posts latest survival data for lung cancer therapy ivonescimab ...

Merck projects $200 million in tariff costs, boosts U.S. manufacturing plans, and continues M&A efforts amid external pressures and shifting market dynamics.

So far, SpringWorks – which was spun out of Pfizer in 2017 and has recently received FDA approval for a second therapy for a ...

The transaction, which sources say could be agreed upon as soon as Monday, would price SpringWorks at $47 per share, totaling ...

BMO Capital analyst Evan Seigerman lowered the firm’s price target on Merck (MRK) to $82 from $89 and keeps a Market Perform rating on the ...